Suplay ng Tocilizumab mababa hanggang Disyembre – DOH

Manila, Philippines – Mananatiling mababa ang suplay ng Tocilizumab, anti-inflammatory off-label medication na ginagamit para sa COVID-19 patients hanggang sa katapusan ng taon, ayon sa Department of Health.

“For example tocilizumab, so the manufacturer has already notified that there will really be some severe stockouts until December 2021. That is because of the Delta wave that is being experienced across countries and therefore the increase in global demand for these products,” saad ni Dr. Melissa Guerrero, head ng pharmaceutical division ng DOH.

Samantala, stable naman aniya ang suplay ng Remdesivir.

“For Remdesivir, I think the demand and the supply is more stable. We are monitoring the stock levels in our hospitals, especially the COVID referral hospitals and there are stocks available.”

“But at the supply side, there’s critical level already so we are making sure and doing our best to communicate with the industry in order to facilitate the restocking in order to prepare for the worst case scenario,” punto pa ng opisyal.

Samantala, nagpaalala si Guerrero sa publiko na huwag itong inumin ng walang payo ng doktor at huwag bumili sa black market.

“They should be in a hospital, the medicine should be prescribed by a doctor, should be administered by the doctor and they cannot just access the drugs in the black market.”

“We’re balancing the setting of the SRP (suggested retail price) with the available supply globally, so right now we have set the SRP for Remdesivir anywhere from P1,500 to P8,200. But we’re reviewing now the prices were working with the Department of Trade & Industry,” paliwanag pa ni Guerrero.

“In fact there will be a meeting at the National Price Coordinating Council because we have been receiving a lot of complaints from patients that there’s overpricing, really.” RNT/FGDC

Suplay ng Tocilizumab mababa hanggang Disyembre – DOH
Source: Filipino Pinoys